News for The Ensign Group, Inc. (EGB.BE)

Conference Call and Webcast scheduled for tomorrow, February 4, 2021 at 10:00 am PT SAN JUAN CAPISTRANO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- The...

SAN JUAN CAPISTRANO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (NASDAQ:ENSG), the parent company of the Ensign™ group of ...

Today's Daily Dose brings you news about the FDA lifting the partial clinical hold on Marker Therapeutics' phase II post-transplant acute myeloid leukemia trial; Rhythm selling its Rare Pediatric Disease Priority Review Voucher for $100 million; Hoth Therapeutics' financing agreement; Millendo discontinuing further development of MLE-301 for the treatment of menopausal vasomotor symptoms.